Navigation Links
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
Date:9/11/2009

we will continue our efforts to bring new and effective treatments for these patients," said Dr. Marc Cluzel, Senior Vice President, Research and Development sanofi-aventis. "We remain committed to the other ongoing Phase 3 trials of aflibercept in colorectal cancer, non-small cell lung cancer, and hormone-refractory metastatic prostate cancer."

Three Phase 3 studies continue, each of which is currently over 70 percent enrolled:

  • VELOUR study: 2nd-line metastatic colorectal cancer in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI)
  • VITAL study: 2nd-line non-small cell lung cancer in combination with docetaxel
  • VENICE study: 1st-line hormone-refractory metastatic prostate cancer in combination with docetaxel and prednisone

About Pancreatic Cancer

Each year in the United States, more than 42,000 individuals are diagnosed with pancreatic cancer and over 35,000 die. The prognosis is generally poor; less than five percent of those diagnosed are still alive five years after diagnosis. Gemcitabine is considered the standard backbone of first-line treatment in patients with first-line metastatic pancreatic cancer.

About Aflibercept

Aflibercept is an anti-angiogenesis inhibitor with a unique mechanism of action. This fusion protein binds all forms of Vascular Endothelial Growth Factor-A (VEGF-A), as well as VEGF-B and placental growth factor (PIGF), additional angiogenic growth factors that appear to play a role in tumor angiogenesis and inflammation. Aflibercept has been shown to bind VEGF-A, VEGF-B, and PlGF with higher affinity than their natural receptors.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is liste
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.; sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
2. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
3. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
4. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
5. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
8. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
9. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
10. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
11. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... RALEIGH, N.C. , April 17, 2015 /PRNewswire/ ... of the Integrated Embolic Protection™ filter platform for ... completion of a $5.6 million Series B financing ... stage venture firm with a focus on medical ... medicine. The round also included Mountain Group Partners, ...
(Date:4/17/2015)... -- AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / ... of its exchange offer to acquire all of the outstanding ... New York City time, on May ... also voluntarily withdrew its initial Notification and Report Form under ... FTC with additional time to review the proposed transaction.  A ...
(Date:4/17/2015)... 17, 2015 Inivata, a ... that their presence at the 2015 American Association for Cancer ... co-founder Nitzan Rosenfeld and a poster presentation. ... th - 22 nd . The presentation, ... , forms part of a session on ...
Breaking Medicine Technology:Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
... Alberta, Dec. 15, 2011 Fero Industries, Inc. ... Company,s Mexican operating subsidiary, has completed the registration ... federal and local government institutions within Mexico. This ... of certifications, allows the Company to provide coverage ...
... 2011 MedShape, Inc., the industry leader in innovative shape ... a patent from the United States Copyright and Patent Office ... U.S. Patent No. 8,069,858, was granted December 6, 2011 for ... Shape memory polymers are advanced materials that ...
Cached Medicine Technology:Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico 2Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico 3MedShape, Inc. Awarded U.S. Patent for Deploying Shape Memory Polymer Devices in Medical Applications 2
(Date:4/18/2015)... 18, 2015 Compare-autoinsurance.org has released a ... reliable auto insurance policy . , Clients should ... insurance quotes online is safe and reliable. An insurance ... quotes are displayed on a single web page, so ... , It is now possible to compare online car ...
(Date:4/18/2015)... April 18, 2015 Carinsurancesavings.biz has released ... plans are cheaper during Spring. , Spring ... insurance plan. Drivers should make sure they compare the ... vehicles. Clients can learn more about Spring car insurance ... , Auto insurance quotes are becoming more and more ...
(Date:4/18/2015)... April 18, 2015 "I recognized the ... in healthcare facilities," said an inventor from Cincinnati, Ohio. ... system." , He developed the Slyde Door to offer ... in healthcare facilities. It provides convenient storage space for ... more stretchers available for patients. , This offers ...
(Date:4/18/2015)... April 18, 2015 Review of Ophthalmology ... a ‘Strategies for Success’ program for cataract surgeons attending ... in San Diego, where eye surgeon Jeffrey L. Martin, ... invitation-only event. Dr. Martin is the Managing Partner of ... Ophthalmology chose Dr. Martin to lead this year’s discussion ...
(Date:4/18/2015)... April 18, 2015 Lowcostcarinsuranceprice.com has released ... rates have on auto insurance prices . ... rates of vehicle theft may have to pay more ... liability auto insurance policies can also offer protection against ... now be compared online on a single website: ...
Breaking Medicine News(10 mins):Health News:A Guide For Avoiding Online Auto Insurance Scams! 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2
... Aug. 7 Duane Reade Holdings, Inc. announced today that ... the "Issuers"), had closed their offering of $300.0 million aggregate ... (the "Notes"). The Notes bear interest at an annual ... representing a yield to maturity of 12.375%. The Notes ...
... children may miss the target, study finds , FRIDAY, ... for children may have to be revised, say researchers ... indicator of high cholesterol in kids. , In 2008, ... screening guidelines that recommended a cholesterol check for children ...
... , NEW YORK, Aug. 7 WebMD Health Corp. (Nasdaq: ... today announced that executives of WebMD are scheduled to participate at the ... at 1:00 p.m. ET. , , Investors, ... audio broadcast of the presentation over the Internet. The broadcast can ...
... But researchers must figure out how to keep new beta ... European scientists have identified a transcription factor that plays a ... beta cells, and the finding could lead to a new ... the researchers found that when a gene called Pax4 is ...
... , MORGANTOWN, W.Va., Aug. 7 The first ... homeless patients are more likely to arrive at the hospital by ... , One-third of homeless patients arrived by ambulance ... the researchers. , , Analyzing almost half a ...
... , OAKLAND, Calif., Aug. 7 California domestic violence ... help keep abuse survivors safe, thanks to a new program created ... , , The program, funded by a $130,000 ... designed to teach domestic violence advocates about the use of new ...
Cached Medicine News:Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:Cholesterol Screening Shouldn't Rely on Kids' Weight 2Health News:Researchers Produce First Nationwide Study of Homeless in ERs 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 3Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 4
Long handle occluders are approximately 9 inches long....
Basic external reading model....
Manual Lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: